SEC Company Response from Bionano Genomics, Inc. (BNGO) (CIK 0001411690) (BNGO) — Jul 13, 2018
Bionano Genomics, Inc. (BNGO) (CIK 0001411690)
Date: July 13, 2018 · CIK: 0001411690 · Accession: 0001193125-18-217318
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225970
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Re: Bionano Genomics, Inc. Registration Statement on Form S-1 Filed June 28, 2018 File No. 333-225970
Dear Ms. Ravitz:
On behalf of Bionano Genomics, Inc. (“Bionano” or the “Company”), we are responding to the comments (the “Comments”) of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter, dated July 12, 2018 (the “Comment Letter”), relating to the above referenced Registration Statement on Form S-1 (the “Registration Statement”).
In response to the Comments set forth in the Comment Letter, the Company has revised the Registration Statement and is publicly filing via EDGAR an Amended Registration Statement on Form S-1 (the “Amended Registration Statement”) with this response letter.
For ease of reference, set forth below are the Company’s responses to the Comments. The numbering of the paragraphs below corresponds to the numbering of the Comments, which for your convenience we have incorporated into this response letter. Page references in the text of this response letter correspond to the page numbers of the Amended Registration Statement. Capitalized terms used in this letter but not otherwise defined herein shall have the meanings set forth in the Amended Registration Statement.
Staff Comments and Company Responses
Overview, page 1
1. We note your response to prior comment 2. Please revise to disclose the amount of revenue received from each of the customers you mention.
Response: The Company respectfully acknowledges the Staff’s comment and has revised pages 1 and 66 of the Registration Statement.
Use of Proceeds, page 46
2. Please expand your response to prior comment 5 to clarify why you will be unable to identify the amount to be used for each purpose disclosed. Otherwise, revise to provide the approximate amount intended to be used for each purpose you disclose. Refer to Item 504 of Regulation S-K.
Cooley LLP 4401 Eastgate Mall San Diego, CA 92121
t: (858) 550-6000 f: (858) 550-6420 cooley.com
United States Securities and Exchange
Commission
July 13, 2018
Page Two
Response: The Company respectfully acknowledges the Staff’s comment and has revised page 46 of the Registration Statement.
Results of Operations, page 56
3. It appears from your revisions in response to prior comment 7 that product volume decreased for the period ended March 31, 2018. If so, quantify and explain the reasons for the decrease.
Response: The Company respectfully acknowledges the Staff’s comment and has revised page 56 of the Registration Statement with respect to the financial information as of the interim period ended June 30, 2018.
Government Regulation, page 84
4. We note your response to prior comment 3. Please revise your disclosure to discuss the regulatory requirements regarding laboratory developed tests and how these regulatory requirements differ when the tests are developed wholly or partly outside of the laboratory that offers them. Also address in your disclosure whether you have pursued or intend to pursue regulatory approval prior to sale to cytogenetics labs.
Response: The Company respectfully acknowledges the Staff’s comment and has revised page 86 of the Registration Statement.
*************************
The Company respectfully requests the Staff’s assistance in completing the review of the Amended Registration Statement as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding the Amended Registration Statement or this response letter to me at (858) 550-6029.
Sincerely,
Cooley LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP James Pennington VIA EDGAR +1 858 550 6029 jpennington@cooley.com July 13, 2018 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 3030 100 F Street, N.E. Washington, D.C. 20549 Attn: Amanda Ravitz Re: Bionano Genomics, Inc. Registration Statement on Form S-1 Filed June 28, 2018 File No. 333-225970 Dear Ms. Ravitz: On behalf of Bionano Genomics, Inc. (“Bionano” or the “Company”), we are responding to the comments (the “Comments”) of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter, dated July 12, 2018 (the “Comment Letter”), relating to the above referenced Registration Statement on Form S-1 (the “Registration Statement”). In response to the Comments set forth in the Comment Letter, the Company has revised the Registration Statement and is publicly filing via EDGAR an Amended Registration Statement on Form S-1 (the “Amended Registration Statement”) with this response letter. For ease of reference, set forth below are the Company’s responses to the Comments. The numbering of the paragraphs below corresponds to the numbering of the Comments, which for your convenience we have incorporated into this response letter. Page references in the text of this response letter correspond to the page numbers of the Amended Registration Statement. Capitalized terms used in this letter but not otherwise defined herein shall have the meanings set forth in the Amended Registration Statement. Staff Comments and Company Responses Overview, page 1 1. We note your response to prior comment 2. Please revise to disclose the amount of revenue received from each of the customers you mention. Response: The Company respectfully acknowledges the Staff’s comment and has revised pages 1 and 66 of the Registration Statement. Use of Proceeds, page 46 2. Please expand your response to prior comment 5 to clarify why you will be unable to identify the amount to be used for each purpose disclosed. Otherwise, revise to provide the approximate amount intended to be used for each purpose you disclose. Refer to Item 504 of Regulation S-K. Cooley LLP 4401 Eastgate Mall San Diego, CA 92121 t: (858) 550-6000 f: (858) 550-6420 cooley.com United States Securities and Exchange Commission July 13, 2018 Page Two Response: The Company respectfully acknowledges the Staff’s comment and has revised page 46 of the Registration Statement. Results of Operations, page 56 3. It appears from your revisions in response to prior comment 7 that product volume decreased for the period ended March 31, 2018. If so, quantify and explain the reasons for the decrease. Response: The Company respectfully acknowledges the Staff’s comment and has revised page 56 of the Registration Statement with respect to the financial information as of the interim period ended June 30, 2018. Government Regulation, page 84 4. We note your response to prior comment 3. Please revise your disclosure to discuss the regulatory requirements regarding laboratory developed tests and how these regulatory requirements differ when the tests are developed wholly or partly outside of the laboratory that offers them. Also address in your disclosure whether you have pursued or intend to pursue regulatory approval prior to sale to cytogenetics labs. Response: The Company respectfully acknowledges the Staff’s comment and has revised page 86 of the Registration Statement. ************************* The Company respectfully requests the Staff’s assistance in completing the review of the Amended Registration Statement as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding the Amended Registration Statement or this response letter to me at (858) 550-6029. Sincerely, Cooley LLP /s/ James Pennington James Pennington cc: R. Erik Holmlin, Ph.D., Bionano Genomics, Inc. Cooley LLP 4401 Eastgate Mall San Diego, CA 92121 t: (858) 550-6000 f: (858) 550-6420 cooley.com